CN116472065A - 治疗皮肌炎的方法 - Google Patents

治疗皮肌炎的方法 Download PDF

Info

Publication number
CN116472065A
CN116472065A CN202180076442.2A CN202180076442A CN116472065A CN 116472065 A CN116472065 A CN 116472065A CN 202180076442 A CN202180076442 A CN 202180076442A CN 116472065 A CN116472065 A CN 116472065A
Authority
CN
China
Prior art keywords
dermatomyositis
fusion protein
muscle
composition
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180076442.2A
Other languages
English (en)
Chinese (zh)
Inventor
保罗·P·坦布里尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of CN116472065A publication Critical patent/CN116472065A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
CN202180076442.2A 2020-10-05 2021-10-05 治疗皮肌炎的方法 Pending CN116472065A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063087577P 2020-10-05 2020-10-05
US63/087,577 2020-10-05
PCT/US2021/053540 WO2022076388A1 (en) 2020-10-05 2021-10-05 Methods of treating dermatomyositis

Publications (1)

Publication Number Publication Date
CN116472065A true CN116472065A (zh) 2023-07-21

Family

ID=81126239

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180076442.2A Pending CN116472065A (zh) 2020-10-05 2021-10-05 治疗皮肌炎的方法

Country Status (10)

Country Link
US (1) US20230357442A1 (https=)
EP (1) EP4225372A4 (https=)
JP (1) JP2023544409A (https=)
KR (1) KR20230084210A (https=)
CN (1) CN116472065A (https=)
AU (1) AU2021358027A1 (https=)
CA (1) CA3172994A1 (https=)
IL (1) IL301713A (https=)
MX (1) MX2023004034A (https=)
WO (1) WO2022076388A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116313071B (zh) * 2023-01-16 2023-09-08 南方医科大学南方医院 一种预测初诊皮肌炎患者发生快速进展型间质性肺病的风险模型的构建方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103118737A (zh) * 2010-04-21 2013-05-22 艾博特生物技术有限公司 用于治疗药剂的受控输送的可佩戴自动注射装置
CN111201246A (zh) * 2017-07-11 2020-05-26 亚力兄制药公司 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
WO2020198062A1 (en) * 2019-03-22 2020-10-01 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2794359A (en) * 1953-09-22 1957-06-04 Lyman Gun Sight Corp Automatic primer feed device
EP3511339B1 (en) * 2012-02-20 2025-04-09 IPC Research, LLC Polypeptides binding to human complement c5
CN108476328B (zh) * 2016-01-04 2021-04-20 瑞典爱立信有限公司 改进的网络记录设备
AU2022283254A1 (en) * 2021-05-25 2023-11-30 Alexion Pharmaceuticals, Inc. Kidney active fusion proteins and methods of treatment using the same
JP2024534083A (ja) * 2021-08-20 2024-09-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体代替経路阻害剤を用いて鎌状赤血球症又はベータサラセミアを治療する方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103118737A (zh) * 2010-04-21 2013-05-22 艾博特生物技术有限公司 用于治疗药剂的受控输送的可佩戴自动注射装置
CN111201246A (zh) * 2017-07-11 2020-05-26 亚力兄制药公司 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
WO2020198062A1 (en) * 2019-03-22 2020-10-01 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STANISLAS FAGUER ，ET AL: ""Complement C5-blocking Agent in Refractory Dermatomyositis"", 《J RHEUMATOL . 》, vol. 45, no. 12, 15 September 2018 (2018-09-15), pages 1710 - 1711, XP093207862, DOI: 10.3899/jrheum.180060 *

Also Published As

Publication number Publication date
MX2023004034A (es) 2023-06-09
KR20230084210A (ko) 2023-06-12
CA3172994A1 (en) 2022-04-14
WO2022076388A1 (en) 2022-04-14
IL301713A (en) 2023-05-01
EP4225372A1 (en) 2023-08-16
US20230357442A1 (en) 2023-11-09
JP2023544409A (ja) 2023-10-23
AU2021358027A1 (en) 2023-05-11
EP4225372A4 (en) 2024-11-06

Similar Documents

Publication Publication Date Title
CN111315411B (zh) 高浓度抗c5抗体制剂
TWI634126B (zh) 抗－N3pGlu 類澱粉β肽抗體及其用途
JP6460993B2 (ja) 血管疾患及びその合併症の処置
CN117024583A (zh) 抗N3pGlu淀粉状蛋白β肽抗体及其用途
CN110898220B (zh) 抗IL17a抗体的水性药物组合物及其用途
US20190010224A1 (en) Formulations of engineered anti-il-10 antibodies
CN110960490A (zh) 一种抗egfr抗体偶联药物组合物及其用途
WO2023116751A1 (zh) 抗人血管生成素3纳米抗体及其应用
IL293367A (en) Pharmaceutical formulations and dosage regimens for antibodies to factor xi/xia
CN116472065A (zh) 治疗皮肌炎的方法
KR20220012894A (ko) 전신 경화증의 치료 방법
WO2019001560A1 (zh) 一种pcsk-9抗体药物组合物及其用途
KR20230093499A (ko) 인간 대상체에서 타우를 감소시키는 방법
EP4635988A1 (en) Bispecific fusion protein targeting tnf-? and il-17a, and use thereof
US11479603B2 (en) Polypeptide and antibody bound to polypeptide
CA3020339C (en) Compositions and methods for treating pancreatitis and pain with death receptor agonists
JP2025504779A (ja) 抗ｔｒｂｖ９抗体の医薬組成物およびその使用
WO2025166169A1 (en) Compositions, doses, and methods for treatment of c1s mediated diseases and disorders
WO2025081130A1 (en) Use of anti-asc antibody in the treating of ocular disorders
HK40120923A (zh) 用於治疗或预防疾病症状的抗肾上腺髓质素(adm)结合剂
CN120000779A (zh) 抗il-5抗体治疗与嗜酸性粒细胞升高相关疾病的用途
JP2026503045A (ja) Ｔｓｌｐ抗体を使用して喘息を治療するための方法
HK40102408A (zh) 含抗lag-3抗体的药物组合物及其用途
HK40102408B (zh) 含抗lag-3抗体的药物组合物及其用途
HK40023297A (en) Polypeptide and antibody bound to polypeptide

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination